Freenome

Freenome develops blood-based tests for early cancer detection using its multiomics platform that combines computational biology, machine learning, and advanced genomics. The company has raised $1.35B in total funding including a $254M Series E in February 2024 led by T. Rowe Price and Fidelity Investments. Freenome's initial programs focus on colorectal and lung cancer with a pipeline of single-cancer and multi-cancer tests under development. The company operates PREEMPT CRC (>40,000-participant study for colorectal cancer screening) and PROACT LUNG (up to 20,000 participants for lung screening validation). Setting a new pace for early cancer detection with the ease of a standard blood draw.